Mayo Clinic Health System Tops AMC Brand Ranking for 2nd Year

Mayo Clinic Health System

Mayo Clinic Health System is the world’s strongest Academic Medical Centre (AMC) brand for the second year running. Brand Finance, the world’s leading independent brand valuation consultancy, has released its second annual AMC global brand ranking.

Leadership

44% of healthcare professionals note Mayo Clinic’s leadership in integrating technologies such as robotics, digital imaging, and AI into its healthcare services, a key driver of reputation and brand strength. Mayo Clinic’s brand is also getting stronger, boasting a Brand Strength Index (BSI) score increase of 1.2 points year-on-year to 86.9/100.

Hugo Hensley, Valuation Director, Brand Finance, commented:

“In the dynamic realm of healthcare, marked by the rising prominence of AI and telemedicine, AMCs are racing to seamlessly integrate these transformative trends. Our research at Brand Finance highlights the importance of staying at the vanguard of technological progress. Innovations in these high-profile categories not only bring global attention to an institution, but now rank among the attributes most important in driving a hospital’s overall reputation.”

US-based brands claim seven out of the top ten spots due to widespread global recognition, however, five out of six non-U.S. regional leading AMCs achieved higher Brand Strength Index scores in 2024 compared to 2023. Both the All India Institute of Medical Sciences (AIIMS) and Singapore General Hospital (SGH) entered the top four strongest global brands, with AIIMS securing the third position and SGH as the fourth strongest.

Another notable trend from the 2024 rankings is the staying power of a newsmaking medical breakthrough. Nearly 60 years after performing the first heart transplant, Groote Schuur in Cape Town ranks fifth in the world as “known for scientific breakthroughs,” and France’s Pitié-Salpêtrière Hospital, the pioneer of the first heart transplant in Europe, secured the fourth spot for the same metric.

An attachment to Harvard University’s brand may to boost a brand’s reputation as the place to be for excellence in research, as three out of the top six brands recognized for “attracting the top medical research talent” are affiliated with Harvard (Brigham & Women’s, Mass General, Dana-Farber Cancer Institute).

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”